Markman, Maurie.
Surrogate endpoints of efficacy [electronic resource] / Maurie Markman. - London : Henry Stewart Talks, 2018. - 1 online resource (1 streaming video file (33 min.) : color, sound). - Cancer therapy : latest thinking in efficacy and toxicity, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity. .
Animated audio-visual presentation with synchronized narration. Title from title frames. Updated version of a talk first published in 2009.
Contents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized.
Access restricted to subscribers.
Mode of access: World Wide Web.
2040 Henry Stewart Talks
Antineoplastic agents.
Cancer--Chemotherapy.
Cancer--Treatment--Evaluation.
Clinical trials.
Outcome assessment (Medical care)
Antineoplastic Agents--administration & dosage.
Antineoplastic Agents--therapeutic use.
Biomarkers.
Clinical Trials as Topic.
Endpoint Determination.
Goals.
Neoplasms--prevention & control.
Neoplasms--therapy.
Treatment Outcome.
Surrogate endpoints of efficacy [electronic resource] / Maurie Markman. - London : Henry Stewart Talks, 2018. - 1 online resource (1 streaming video file (33 min.) : color, sound). - Cancer therapy : latest thinking in efficacy and toxicity, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity. .
Animated audio-visual presentation with synchronized narration. Title from title frames. Updated version of a talk first published in 2009.
Contents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized.
Access restricted to subscribers.
Mode of access: World Wide Web.
2040 Henry Stewart Talks
Antineoplastic agents.
Cancer--Chemotherapy.
Cancer--Treatment--Evaluation.
Clinical trials.
Outcome assessment (Medical care)
Antineoplastic Agents--administration & dosage.
Antineoplastic Agents--therapeutic use.
Biomarkers.
Clinical Trials as Topic.
Endpoint Determination.
Goals.
Neoplasms--prevention & control.
Neoplasms--therapy.
Treatment Outcome.